Evidence map›Paper›PMID 34003459›Full record

ReviewCNS drugs2021

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.

Robert L Findling, Shawn A Candler, Azmi F Nasser, Stefan Schwabe, Chungping Yu, Jennie Garcia-Olivares, Welton O'Neal, Jeffrey H Newcorn

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Robert L FindlingVCU Department of Psychiatry, 501 North 2nd Street, Richmond, VA, 23298-0308, USA. Robert.Findling@vcuhealth.org.
Shawn A CandlerSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Azmi F NasserSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Stefan SchwabeSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Chungping YuSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Jennie Garcia-OlivaresSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Welton O'NealSupernus Pharmaceuticals, Inc., Rockville, MD, USA.
Jeffrey H NewcornDepartments of Psychiatry and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Supernus Pharmaceuticals (United States) · USChildren's Hospital of Richmond at VCU · USIcahn School of Medicine at Mount Sinai · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viloxazine has a long history of clinical use in Europe as an antidepressant, and has recently been repurposed into an extended-release form for the treatment of attention-deficit/hyperactivity disorder in the USA. An immediate-release formulation was approved for the treatment of depression in the UK in 1974, and was subsequently marketed there and in several European countries for 30 years with no major safety concerns. In contrast to first-generation antidepressants (e.g., tricyclic antidepressants, monoamine oxidase inhibitors), viloxazine was associated with a relatively low risk for cardiotoxicity. Gastrointestinal symptoms were the most commonly reported side effects. The therapeutic effects of viloxazine are thought to be primarily the result of its action as a norepinephrine reuptake inhibitor, although in vitro and preclinical in vivo animal data suggest that viloxazine may also impact the serotoninergic system. This review summarizes the evolving knowledge of viloxazine based on information from previously published preclinical and clinical investigations, and acquired unpublished historical study reports from both open-label and blinded controlled clinical trials. We review the chemical properties, mechanism of action, safety, and tolerability across these studies, and discuss the contemporary rationale for the development of this agent as an extended-release oral formulation for the treatment of attention-deficit/hyperactivity disorder.

Indexed as

Administration, OralAdrenergic Uptake InhibitorsAnimalsAttention Deficit Disorder with HyperactivityCentral Nervous System DiseasesDelayed-Action PreparationsHumansViloxazineAdrenergic Uptake InhibitorsDelayed-Action PreparationsViloxazine

Identifiers

PMID34003459
PMCPMC8219567
OpenAlexW3160925470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.